[8-K] LB PHARMACEUTICALS INC Reports Material Event
LB Pharmaceuticals (NASDAQ: LBRX) announced its Q1 2026 financial results, reporting a widened net loss of $19.1 million due to increased R&D and G&A expenses. The company has a strong cash position of $365.6 million, projected to fund operations into Q2 2029, supporting the advancement of its lead drug LB-102 through multiple clinical trials for neuropsychiatric indications. Key trials include the pivotal Phase 3 NOVA-2 for acute schizophrenia, Phase 2 ILLUMINATE-1 for bipolar depression, and a planned Phase 2 for adjunctive major depressive disorder, with topline data expected between late 2027 and early 2029.
MAY 13·TradingView▲
LBRX: LB-102 demonstrates rapid efficacy and strong safety in late-stage trials for major neuropsychiatric disorders
LB-102, a novel derivative of amisulpride from LBRX, is showing promising results in late-stage trials for schizophrenia, bipolar depression, and adjunctive Major Depressive Disorder (MDD). The drug demonstrates rapid and robust efficacy alongside a favorable safety profile. Strong financial backing and intellectual property position are expected to facilitate its expansion into other neuropsychiatric indications.
MAR 20·MarketBeat▲
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029
LB Pharmaceuticals CEO Heather Turner outlined milestones for its lead candidate LB-102, targeting Phase 3 schizophrenia data in H2 2027, Phase 2 bipolar depression data in Q1 2028, and adjunctive MDD data in H1 2029. The company has secured funding through Q2 2029, enabling NDA-supporting studies and a safety study for schizophrenia. Turner highlighted LB-102's potential differentiation through rapid onset and no titration, positioning it as the first benzamide expected in the U.S. market.
